Panupun Limpachayaporn

Dr. Panupun Limpachayaporn

Silpakorn University, Nakhon Pathom, Thailand
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
PLPanupun Limpachayaporn
Panupun Limpachayaporn
MSMichael Schäfers
Michael Schäfers
GHGünter Haufe
Günter Haufe
Caspases-3 and -7 play an essential role in apoptosis. Isatin sulfonamides have been identified as potent inhibitors of these executing caspases. Besides pharmacological application, these compounds can also serve as recognition units to target caspases using positron emission tomography (PET) and single-photon emission computed tomography (SPECT) when labeled with a positron or a gamma emitter. Fluorinated, alkylated, arylated isatin derivatives, in addition to derivatives modified with heterocycles, have been prepared in order to improve their binding potency, selectivity and metabolic stability. Structural optimization has led to stable, highly active inhibitors, which after labeling have been applied in PET studies in tumor mouse models and for first preclinical and clinical investigations with healthy human volunteers. The results support further development of such radiotracers for clinical apoptosis imaging.


14 November 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PLPanupun Limpachayaporn
Panupun Limpachayaporn
SWStefan Wagner
Stefan Wagner
Klaus KopkaKlaus Kopka
Klaus Kopka
OSOtmar Schober
Otmar Schober
MSMichael Schäfers
Michael Schäfers
GHGünter Haufe
Günter Haufe

29 May 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PLPanupun Limpachayaporn
Panupun Limpachayaporn
SWStefan Wagner
Stefan Wagner
Klaus KopkaKlaus Kopka
Klaus Kopka
SHSven Hermann
Sven Hermann
MSMichael Schäfers
Michael Schäfers
GHGünter Haufe
Günter Haufe

1 June 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PLPanupun Limpachayaporn
Panupun Limpachayaporn
BRBurkhard Riemann
Burkhard Riemann
Klaus KopkaKlaus Kopka
Klaus Kopka
OSOtmar Schober
Otmar Schober
MSMichael Schäfers
Michael Schäfers
GHGünter Haufe
Günter Haufe

20 April 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SOSittisak Oekchuae
Sittisak Oekchuae
JSJitnapa Sirirak
Jitnapa Sirirak
PCPurin Charoensuksai
Purin Charoensuksai
PWPawaris Wongprayoon
Pawaris Wongprayoon
NCNatthaya Chuaypen
Natthaya Chuaypen
PLPanupun Limpachayaporn
Panupun Limpachayaporn
Target cancer drug therapy is an alternative treatment for advanced hepatocellular carcinoma (HCC) patients. However, the treatment using approved targeted drugs has encountered a number of limitations, including the poor pharmacological properties of drugs, therapy efficiency, adverse effects, and drug resistance. As a consequence, the discovery and development of anti-HCC drug structures are therefore still in high demand. Herein, we designed and synthesized a new series of 1,2,3-triazole-cored structures incorporating aryl urea as anti-HepG2 agents. Forty-nine analogs were prepared via nucleophilic addition and copper-catalyzed azide-alkyne cycloaddition (CuAAC) with excellent yields. Significantly, almost all triazole-cored analogs exhibited less cytotoxicity toward normal cells, human embryonal lung fibroblast cell MRC-5, compared to Sorafenib and Doxorubicin. Among them, 2m’ and 2e exhibited the highest selectivity indexes (SI = 14.7 and 12.2), which were ca. 4.4- and 3.7-fold superior to that of Sorafenib (SI = 3.30) and ca. 3.8- and 3.2-fold superior to that of Doxorubicin (SI = 3.83), respectively. Additionally, excellent inhibitory activity against hepatocellular carcinoma HepG2, comparable to Sorafenib, was still maintained. A cell-cycle analysis and apoptosis induction study suggested that 2m’ and 2e likely share a similar mechanism of action to Sorafenib. Furthermore, compounds 2m’ and 2e exhibit appropriate drug-likeness, analyzed by SwissADME. With their excellent anti-HepG2 activity, improved selectivity indexes, and appropriate druggability, the triazole-cored analogs 2m’ and 2e are suggested to be promising candidates for development as targeted cancer agents and drugs used in combination therapy for the treatment of HCC.